Product logins

Find logins to all Clarivate products below.


Venous Thromboembolism – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of VTE comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of VTE for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s VTE forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of VTE and the number of new diagnoses of VTE?
  • Of all people diagnosed with VTE, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of VTE over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following VTE subpopulations:

  • Top-line epidemiology – Diagnosed VTE events.
  • Key Populations – Diagnosed DVT events.
  • Key Populations – Diagnosed PE events.
  • Diagnosed VTE events by etiology.
  • Diagnosed VTE events by recurrence.
  • Diagnosed DVT events by treatment scheme.
  • Diagnosed PE events by treatment scheme.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Ventolin HFA) and maintenance therapy to prevent…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD) resulting from insufficient erythropoietin production by impaired kidneys. The primary goal of renal anemia treatment is to…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…